In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity
Ayman Abo Elmaaty, Khaled M. Darwish, Amani Chrouda, Amira A. Boseila, Mohamed A. Tantawy, Sameh S. Elhady, Afzal B. Shaik, Muhamad Mustafa, Ahmed A. Al‐Karmalawy
Abstract
< 0.001) reduced the concentration of VEGFR-2, while the lowest inhibition was achieved in MBZ-loaded MMs, which was even much better than the reference drug sorafenib. Collectively, the investigated benzimidazole anthelmintics could be encountered as lead compounds for further structural modifications and thus better anticancer activity, and that was accomplished through studying their structure-activity relationships.
Topics & Concepts
PharmacologyBenzimidazoleAngiogenesisChemistryCancer cellCytotoxicityApoptosisIn vitroCancerCancer researchMedicineBiochemistryInternal medicineOrganic chemistryBioactive Compounds and Antitumor AgentsSynthesis and biological activitySynthesis and Biological Evaluation